Lipidomics: a promising cancer biomarker

  title={Lipidomics: a promising cancer biomarker},
  author={Furong Yan and Hong Zhao and Yiming Zeng},
  journal={Clinical and Translational Medicine},
The prevention, diagnosis and targeted therapies of cancer are important in cancer controlling and treatment. The present challenge about cancer biomarker still remains in identifying the special biomarkers for predicting cancer risk and assessing patient’s response during anticancer treatment. Lipidomics, in simple definition is the quantification of all lipids in a confined biological entity. Lipids play roles in membrane structure, energy storage, and signal transduction as well as in human… 
A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
The two-lipid signature was able to identify EOC patients with an especially poor prognosis at the time of diagnosis, and also showed promise for the detection of disease relapse.
Machine Learning: A New Prospect in Multi-Omics Data Analysis of Cancer
It can be concluded that the use of artificial intelligence technologies such as machine learning can have revolutionary roles in the fight against cancer.
Lipidomic landscape in cancer: Actionable insights for membrane‐based therapy and diagnoses
An overview of lipid membranes and how their properties affect cellular functions is provided and how the rewiring of lipid metabolism impacts the lipidomic landscape of cancer cell membranes and influences the characteristics of cancer cells is discussed.
Abundant circulating lipids — a new opportunity for NSCLC detection?
Key aspects that could facilitate the clinical implementation of this diagnostic tool by mass spectrometry of a targeted panel of lipids and similar tools in other fields of application are discussed.
Lipidomics in psoriatic disease: The new kid on the omics block
Omega‐3 polyunsaturated fatty acid has been shown to suppress inflammatory cell infiltration and epidermal hyperplasia by inhibiting interleukin‐23 production by dendritic cells in a mouse model.
Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients.
A combination of metabolites was identified that distinguished between BC and controls as well as between molecular subtypes, and was predictive for overall survival, suggesting that these metabolites represent promising biomarkers and, moreover, that they may be functionally relevant for tumor progression.
Triple Negative Breast Cancer Detection Using LC-MS/MS Lipidomic Profiling.
A liquid chromatography-tandem mass spectrometry assay capable of targeted, highly specific and sensitive detection of lipids is employed to propose two diagnostic biomarker panels for triple negative breast cancer/ES-TNBC detection, the first study to propose a diagnostic lipid biomarker panel for TNBC detection.
Lipidomic Signatures for Colorectal Cancer Diagnosis and Progression Using UPLC-QTOF-ESI+MS
Both multivariate and univariate bioinformatics confirmed the relevance of some putative lipid biomarkers to be responsible for the altered metabolic pathways in colorectal cancer.


Advances in Lipidomics for Cancer Biomarkers Discovery
The novel lipidomic biomarkers are reviewed in an effort to underline their role in diagnosis, in prognostic characterization and in prediction of therapeutic outcomes, and a lipidomic investigation through mass spectrometry highlights new insights on molecular mechanisms underlying cancer disease.
Heterogeneity of lipidomic profiles among lung cancer subtypes of patients
It is demonstrated that circulating levels of PS and lysoPS significantly increased, while lysoPE and PE decreased in patients with lung cancer, indicating that lung cancer‐specific and subtype‐specific lipidomics in the circulation are important to understand mechanisms of systemic metabolisms and identify diagnostic biomarkers and therapeutic targets.
The emerging field of lipidomics
  • M. Wenk
  • Biology
    Nature Reviews Drug Discovery
  • 2005
Novel analytical approaches — in particular, liquid chromatography and mass spectrometry — for systems-level analysis of lipids and their interacting partners (lipidomics) now make this field a promising area of biomedical research, with a variety of applications in drug and biomarker development.
Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics
Using lipidomics and bioinformatic and statistical methods, a few out of hundreds plasma apparent lipid molecular species are identified as biomarkers for diagnosis of prostate cancer with a high sensitivity, specificity and accuracy.
Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers
The results indicate the usefulness of lipid profiling in the discrimination between patients with breast cancer and non-carcinoma lesions, which might provide assistance in clinical diagnosis.
A plasma lipidomics strategy reveals perturbed lipid metabolic pathways and potential lipid biomarkers of human colorectal cancer.
Functional lipidomics: Palmitic acid impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose metabolism
The biomedical potential of using altered lipid metabolism as a diagnostic marker for cancerous cells is demonstrated and an opportunity for treating aggressive HCCs by targeting altered C16:0 metabolism is opened.
Sphingolipid signaling pathways as potential therapeutic targets in gliomas.
This review will examine the effects of ceramide and S1P on glioma cells and the therapeutic potential of these pathways.
Roles of bioactive Sphingolipid metabolites in ovarian cancer cell biomechanics
Investigation of the effects of exogenous sphingolipid metabolites on the Young's modulus and cytoskeletal organization of cells representing aggressive ovarian cancer demonstrates that the elasticity ofaggressive ovarian cancer cells decreased, and sphingosine treatment caused a ~30% increase in the average elasticity which was associated with a more defined actin cytoskeleton organization.
Lysophospholipids are potential biomarkers of ovarian cancer.
  • R. Sutphen, Yan Xu, J. Krischer
  • Medicine, Biology
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2004
LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.